Biochemistry

Learning Objectives

• Define biochemistry and explain its role as a bridge between organic chemistry and pharmacology
• Classify the four major classes of biomolecules and describe their pharmaceutical relevance
• Explain the difference between catabolism and anabolism using glycolysis as a worked example
• Describe how enzymes function and why they are common drug targets
• Explain the role of nucleic acids in genetic information and its relevance to modern biologic drugs
• Apply biochemical reasoning to explain why a specific drug interacts with a specific biomolecule class

Quick Answer

Biochemistry is the study of the chemical processes occurring inside living organisms — how cells build, break down, and use molecules to sustain life. For pharmacy students, biochemistry is the essential link between organic chemistry (the properties of molecules) and pharmacology (how drugs affect the body), because nearly every drug works by interacting with a biomolecule: an enzyme, a receptor protein, a nucleic acid, or a metabolic pathway. Understanding the four classes of biomolecules (carbohydrates, proteins, lipids, nucleic acids), how metabolism converts and stores energy, how enzymes catalyze life's reactions, and how genetic information is stored and expressed gives pharmacy students the biological vocabulary needed to understand drug mechanisms, side effects, and drug interactions.

Core Content

Why pharmacists need biochemistry, not just organic chemistry

Organic chemistry tells you what a molecule looks like and how it might react; biochemistry tells you what happens when that molecule enters a living system built from proteins, nucleic acids, and metabolic pathways. A statin doesn't just have a certain molecular structure — it competitively inhibits a specific enzyme (HMG-CoA reductase) in a specific metabolic pathway (cholesterol biosynthesis). Without biochemistry, "inhibits HMG-CoA reductase" is just words; with it, you understand exactly why blocking that step lowers cholesterol and why certain other pathways (like CoQ10 synthesis, which shares an early precursor) can be affected as a side consequence.

Biomolecules: the four building blocks of life

Biomolecules are the organic compounds that make up living organisms and carry out biological function. They fall into four major classes:

• Carbohydrates — monosaccharides (e.g., glucose), disaccharides (e.g., sucrose), and polysaccharides (e.g., starch, glycogen) — serve primarily as energy sources and structural components. Glucose in particular is the central currency of cellular energy metabolism.
• Proteins — built from chains of amino acids folded into specific three-dimensional shapes — serve structural roles (collagen), functional/catalytic roles (enzymes), transport roles (hemoglobin), and storage roles. Most drug targets (receptors, enzymes, transporters, ion channels) are proteins, which is why understanding protein structure is central to pharmacology.
• Lipids — including triglycerides, phospholipids, and steroids — form cell membranes (phospholipid bilayers), store energy (triglycerides), and serve as signaling molecules (steroid hormones). Lipid solubility of a drug largely determines whether it can cross cell membranes and the blood-brain barrier.
• Nucleic acids — DNA and RNA — store and transmit genetic information, directing the synthesis of all the body's proteins, including the very enzymes and receptors that drugs target.

Metabolism: catabolism and anabolism working together

Metabolism is the full set of chemical reactions that sustain life, and it splits conceptually into two opposing but linked processes: catabolism, which breaks complex molecules into simpler ones (typically releasing energy), and anabolism, which builds complex molecules from simpler ones (typically consuming energy). A cell is constantly running both processes simultaneously, balancing energy release against biosynthetic demand.

Glycolysis is the clearest worked example of catabolism in action: it converts one molecule of glucose into two molecules of pyruvate in the cytosol, generating a net yield of 2 ATP and 2 NADH per glucose molecule in the process. This pathway matters pharmaceutically far beyond biochemistry lecture halls — glycolysis is a target of interest in cancer metabolism research (many tumor cells rely heavily on glycolysis even in the presence of oxygen, a phenomenon called the Warburg effect), and understanding it is essential background for pharmacy topics like diabetes management, where drugs modulate glucose uptake and processing.

Enzymes: the catalysts that make drug targeting possible

Enzymes are proteins (with some notable RNA-based exceptions called ribozymes) that dramatically accelerate specific biochemical reactions by lowering the activation energy required, without being consumed themselves. Enzymes are one of the most important classes of drug targets because their activity can be selectively increased or decreased by a well-designed molecule that fits into or near their active site — statins inhibiting HMG-CoA reductase, ACE inhibitors blocking angiotensin-converting enzyme, and penicillins inhibiting bacterial transpeptidase enzymes are all examples of drugs whose entire therapeutic logic depends on enzyme biochemistry.

Genetic information: from DNA to drug targets

DNA stores the genetic blueprint that is transcribed into RNA and translated into proteins — the "central dogma" of molecular biology. This matters to pharmacy in two major ways: first, essentially every drug target (enzyme, receptor) is itself a protein product of gene expression, so genetic variation between individuals (pharmacogenomics) can change how a person responds to or metabolizes a drug. Second, an entire modern class of therapies — gene therapy, antisense oligonucleotides, mRNA vaccines, and RNA interference (RNAi) drugs — works by directly targeting or modifying genetic information itself, rather than acting on a downstream protein.

Key Terms

Term	Definition	Related Concept
Biomolecule	An organic compound produced by and essential to living organisms	Carbohydrates, proteins, lipids, nucleic acids
Catabolism	Metabolic breakdown of complex molecules into simpler ones, typically releasing energy	Glycolysis, cellular respiration
Anabolism	Metabolic synthesis of complex molecules from simpler ones, typically consuming energy	Protein synthesis, glycogenesis
Glycolysis	The metabolic pathway converting glucose into pyruvate in the cytosol, yielding ATP and NADH	Cellular respiration, cancer metabolism
Enzyme	A protein (or occasionally RNA) catalyst that accelerates a specific biochemical reaction	Active site, drug target
Active site	The region of an enzyme where substrate binds and the catalyzed reaction occurs	Enzyme inhibition, drug design
Central dogma	The principle that genetic information flows from DNA to RNA to protein	Gene expression, pharmacogenomics
Pharmacogenomics	The study of how genetic variation affects individual drug response and metabolism	Personalized medicine

Common Mistakes

Misconception: Catabolism and anabolism happen at separate times in the body (e.g., catabolism only while fasting, anabolism only after eating). Why it's wrong: Both processes occur continuously and simultaneously in different tissues and even within the same cell; what shifts with feeding/fasting state is the overall balance between the two, not an on/off switch. Correct understanding: Cells constantly run both catabolic and anabolic reactions; hormonal and metabolic signals shift the relative balance toward net breakdown or net synthesis depending on the body's energy state.

Misconception: All enzymes are drug targets in the same straightforward way — inhibiting any enzyme in a pathway will have the same effect. Why it's wrong: Pathways often have multiple regulatory points, feedback loops, and redundant routes; inhibiting different enzymes in the same pathway can have very different magnitudes of effect, and some inhibitions trigger compensatory changes elsewhere. Correct understanding: Effective enzyme-targeted drug design requires identifying rate-limiting or uniquely critical steps (like HMG-CoA reductase in cholesterol synthesis) rather than assuming any enzyme in a relevant pathway is an equally good target.

Misconception: Genetic information only matters for biologic or gene-based drugs, not for ordinary small-molecule medications. Why it's wrong: Since conventional drug targets (enzymes, receptors) are themselves gene products, individual genetic variation in genes encoding those targets or metabolizing enzymes (like CYP450 variants) can significantly affect how a person responds to an ordinary small-molecule drug. Correct understanding: Pharmacogenomics is relevant to essentially all drug classes, not just gene therapies, because genetic variation shapes both drug targets and drug-metabolizing enzymes throughout the body.

Comparison and Connections

Feature	Carbohydrates	Proteins	Lipids	Nucleic Acids
Primary role	Energy source, structure	Catalysis, structure, transport, drug targets	Membranes, energy storage, signaling	Genetic information storage/expression
Pharmacy relevance	Diabetes management, glycolysis-targeted therapy	Most drug targets (enzymes, receptors) are proteins	Determines drug membrane permeability	Basis of pharmacogenomics and gene-based therapies
Monomer unit	Monosaccharide	Amino acid	Fatty acid / glycerol / sterol backbone	Nucleotide

Practice Questions

Recall

1. Name the four major classes of biomolecules. Answer guidance: Carbohydrates, proteins, lipids, and nucleic acids.

2. What are the net products of glycolysis per molecule of glucose? Answer guidance: Two molecules of pyruvate, a net gain of 2 ATP, and 2 NADH.

Understanding

3. Explain why proteins, rather than carbohydrates or lipids, are the most common class of drug target. Answer guidance: Most drug targets — enzymes, receptors, ion channels, transporters — are proteins with specific 3D binding sites that a drug molecule can be designed to fit, whereas carbohydrates and lipids more often serve structural or energy roles rather than acting as selective binding targets.

4. Why does lipid solubility of a drug matter for its ability to reach the brain? Answer guidance: Cell membranes, including those forming the blood-brain barrier, are built from phospholipid bilayers; a sufficiently lipid-soluble (lipophilic) drug can cross these membranes more readily, while highly polar drugs are largely excluded unless actively transported.

Application

5. A new cholesterol-lowering drug is designed to inhibit HMG-CoA reductase. Using biochemical reasoning, explain why this specific enzyme is chosen as the target rather than a later enzyme in the cholesterol synthesis pathway. Answer guidance: HMG-CoA reductase catalyzes the rate-limiting step of cholesterol biosynthesis, so inhibiting it produces a large effect on overall pathway output; targeting a later, non-rate-limiting enzyme would likely have a much smaller effect on final cholesterol levels.

6. A patient metabolizes a standard drug dose unusually slowly, leading to toxicity at normal doses. What biochemical explanation, connected to genetic information, could account for this? Answer guidance: The patient may carry a genetic variant (pharmacogenomic polymorphism) in a CYP450 drug-metabolizing enzyme gene that reduces enzyme activity, causing the drug to accumulate to toxic levels at a dose that would be safe for most patients.

Analysis

7. Compare catabolism and anabolism in terms of energy flow, and explain why a cell needs both processes running simultaneously rather than sequentially. Answer guidance: Catabolism releases energy by breaking down molecules (e.g., glycolysis generating ATP); anabolism consumes that energy to build necessary molecules (proteins, nucleic acids, membrane lipids). Because cells continuously need both energy and new biomolecules to survive and respond to changing conditions, both processes must run concurrently, with regulatory signals shifting the balance rather than switching either off completely.

8. Analyze why understanding the Warburg effect (cancer cells favoring glycolysis even with oxygen present) is relevant to pharmaceutical research. Answer guidance: If cancer cells depend unusually heavily on glycolysis for energy compared to normal cells (which typically prefer oxidative phosphorylation when oxygen is available), this metabolic difference becomes a potential selective vulnerability that researchers can target with drugs designed to disrupt glycolytic enzymes preferentially in tumor cells, while sparing normal tissue more reliant on other pathways.

FAQ

1. Why is biochemistry considered harder or more abstract than organic chemistry for many pharmacy students? Organic chemistry deals with isolated molecules and predictable reaction rules, while biochemistry requires holding multiple interacting systems in mind simultaneously — pathways, regulation, feedback loops, and how molecules behave differently in a living cell versus a test tube — which demands a different, more integrative kind of reasoning.

2. Do all enzymes require cofactors or coenzymes to function? Not all enzymes need them, but many do — cofactors (often metal ions) and coenzymes (often vitamin-derived molecules like NAD+ or coenzyme A) assist catalysis by providing chemical groups or electron transfer capability that the amino acid side chains of the enzyme alone cannot supply.

3. How is glycolysis relevant to a pharmacy student who isn't studying oncology? Glycolysis underlies basic understanding of how the body manages blood glucose, which is directly relevant to diabetes pharmacotherapy, and it's also foundational for understanding cellular energy metabolism referenced throughout pharmacology, toxicology, and exercise physiology topics.

4. What's the practical difference between DNA-targeted drugs and protein-targeted drugs? DNA/RNA-targeted therapies (antisense oligonucleotides, RNAi, mRNA vaccines, gene therapy) act on genetic material itself to change what proteins are made or expressed, while traditional protein-targeted drugs act on already-made proteins (enzymes, receptors) to modulate their activity directly; the two approaches intervene at completely different points in the flow of genetic information to function.

5. Why do some enzyme inhibitor drugs cause unexpected side effects unrelated to their main therapeutic pathway? Many enzymes participate in more than one pathway, or their substrates/products are shared with other pathways; inhibiting an enzyme for its intended effect on one pathway can therefore also reduce output of a related pathway that shares an early precursor, biochemistry, or regulatory mechanism, producing seemingly unrelated side effects.

Quick Revision

• Biochemistry bridges organic chemistry (molecular structure) and pharmacology (drug action in the body).
• The four major biomolecule classes are carbohydrates, proteins, lipids, and nucleic acids.
• Proteins are the most common drug target class because most enzymes, receptors, and transporters are proteins.
• Lipid solubility of a drug determines its ability to cross cell membranes, including the blood-brain barrier.
• Catabolism breaks down molecules and releases energy; anabolism builds molecules and consumes energy; both run simultaneously.
• Glycolysis converts glucose to pyruvate, yielding a net 2 ATP and 2 NADH per glucose molecule.
• The Warburg effect describes cancer cells' unusual reliance on glycolysis even with oxygen present, a potential drug target.
• Enzymes catalyze reactions by lowering activation energy and are common, highly selective drug targets (e.g., statins, ACE inhibitors).
• The central dogma (DNA → RNA → protein) explains how genetic information becomes functional drug targets.
• Pharmacogenomics explains why genetic variation affects individual drug response, relevant to both small-molecule and biologic drugs.

Related Topics

Prerequisites: Organic Chemistry for Pharmacy, Inorganic Pharmaceutical Chemistry

Related Topics: Medicinal Chemistry I, Medicinal Chemistry II, Drug Design and Discovery

Next Topics: Drug Design and Discovery, Chemoinformatics